LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Home・Aktien・Pulmatrix Inc

Pulmatrix Inc

Geschlossen

4.45 2.06

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.38

Max

4.55

Schlüsselkennzahlen
By Trading Economics
Einkommen	672K -877K
EPS	-0.24
Gewinnspanne	-60,266.667
Angestellte	2
EBITDA	671K -877K

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-1.5M 16M
Vorheriger Eröffnungskurs	2.39
Vorheriger Schlusskurs	4.45

Pulmatrix Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Nov. 2025, 16:49 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. Nov. 2025, 15:32 UTC

Akquisitionen, Fusionen, Übernahmen

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. Nov. 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. Nov. 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. Nov. 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. Nov. 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. Nov. 2025, 15:54 UTC

Akquisitionen, Fusionen, Übernahmen

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. Nov. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. Nov. 2025, 15:43 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. Nov. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. Nov. 2025, 15:41 UTC

Akquisitionen, Fusionen, Übernahmen

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. Nov. 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. Nov. 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. Nov. 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. Nov. 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. Nov. 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Nov. 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. Nov. 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. Nov. 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. Nov. 2025, 11:07 UTC

Ergebnisse

Genting: Positive About Prospects Over Longer Term

27. Nov. 2025, 11:06 UTC

Ergebnisse

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: International Travel Demand Expected to Remain Resilient

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Global Growth Expected to Remain Subdued

27. Nov. 2025, 11:04 UTC

Ergebnisse

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. Nov. 2025, 10:59 UTC

Ergebnisse

Genting Bhd 3Q Net Profit Fell 86% on Year

27. Nov. 2025, 10:58 UTC

Ergebnisse

Genting Bhd 3Q Rev Rose 14% on Year

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q Net MYR30.3M

27. Nov. 2025, 10:56 UTC

Ergebnisse

Genting Bhd 3Q EPS MYR0.0079

Peer-Vergleich

Kursveränderung

Pulmatrix Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

Buy

Halten

Sell

Basierend auf 0 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pulmatrix Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.